On June 29, 2026, Helen Sabzevari, serving as President and Chief Executive Officer of PRECIGEN, INC. (NASDAQ:PGEN), executed a substantial divestment of company equity. The transaction involved the sale of 346,836 shares of common stock, resulting in total proceeds of $2,042,864. This financial activity was structured around the exercise of an equivalent number of stock options, followed immediately by the liquidation of the acquired shares.
The timing of the sale is notable within the context of Precigen's recent market performance. The transaction occurred near the stock's 52-week high of $6.04, reflecting a period of intense valuation expansion. Over the preceding year, PGEN shares experienced a documented surge of 262%. The weighted average price for the sold shares was $5.89 per share. According to regulatory filings, the liquidation was not executed as a single block but rather through multiple transactions, with execution prices ranging between $5.75 and $6.04.
Sabzevari's sale was conducted pursuant to a pre-arranged 10b5-1 trading plan, a mechanism designed to facilitate equity transactions in compliance with insider trading regulations. Prior to the liquidation event, the CEO acquired the 346,836 shares by exercising fully vested options. These options carried an exercise price of $2.33 per share, resulting in a total acquisition cost of $808,127. The underlying options are scheduled to expire on February 2, 2032.
Following the completion of these transactions, Ms. Sabzevari's direct ownership position in PRECIGEN remains substantial. She retains a holding of 3,768,872 shares of common stock. Additionally, she maintains a derivative position comprising 500,164 shares in the form of options to purchase common stock. Market analysis from InvestingPro suggests that the stock may currently be trading at a valuation premium relative to its calculated Fair Value. Investors interested in deeper financial metrics, including profitability forecasts and health indicators, may access further data through InvestingPro Tips for PGEN.
The executive sale occurs against a backdrop of recent corporate milestones for Precigen. The company reported its first quarter of 2026 earnings, delivering results that surpassed analyst consensus. Precigen recorded an earnings per share (EPS) of -$0.02, outperforming the forecasted loss of -$0.03. Revenue for the period reached $23.25 million, exceeding the anticipated $20.8 million.
Regulatory progress also marked recent developments for the biotech firm. Precigen secured orphan drug exclusivity from the U.S. Food and Drug Administration (FDA) for PAPZIMEOS, its therapeutic agent for recurrent respiratory papillomatosis. This designation extends market exclusivity through August 2032, effectively preventing the approval of similar drugs for a seven-year period. PAPZIMEOS received full FDA approval in August 2025 and stands as the first approved treatment for adults with this rare disease. It is currently available for distribution in the United States.
Market sentiment regarding the company's pipeline has been reinforced by analyst coverage. H.C. Wainwright reiterated a Buy rating on Precigen shares, maintaining a $14.00 price target. This endorsement followed the company's presentation of follow-up data from its pivotal trial with PAPZIMEOS at a medical conference. These developments underscore significant progress in addressing rare diseases, a sector where Precigen is increasingly positioning itself.
Market data indicates that PGEN closed at $5.25, reflecting a decrease of $0.45 or 7.89%. After-hours trading showed a slight recovery, with the stock advancing to $5.30, up $0.05 or 0.95%. The stock's recent volatility and subsequent executive activity highlight the intersection of clinical milestones, regulatory protections, and market valuation dynamics in the biotechnology sector.